Genomic correlates of response and resistance to immune checkpoint inhibitors in carcinomas of unknown primary-Reference-Cited by-同舟云学术

登录注册会员服务联系我们

Genomic correlates of response and resistance to immune checkpoint inhibitors in carcinomas of unknown primary

Published:2021-05-10 Issue:9 Volume:51 Page:
ISSN:0014-2972
Container-title:European Journal of Clinical Investigation
language:en
Short-container-title:Eur J Clin Invest

Author:

Rassy Elie¹^ORCID,Boussios Stergios²³⁴^ORCID,Pavlidis Nicholas⁵^ORCID

Affiliation:

1. Département de médecine oncologique Gustave Roussy VillejuifF‐94805France

2. Faculty of Life Sciences & Medicine King’s College LondonSchool of Cancer & Pharmaceutical Sciences London UK

3. Medway NHS Foundation Trust Gillingham UK

4. AELIA Organization9th Km Thessaloniki ‐ Thermi Thessaloniki Greece

5. University of Ioannina Ioannina Greece

Publisher

Wiley

Subject

Clinical Biochemistry,Biochemistry,General Medicine

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1111/eci.13583

Reference41 articles.

1. Cancers of unknown primary site: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up

2. Cancer of unknown primary site

3. A new entity of abdominal squamous cell carcinoma of unknown primary;Rassy E;Eur J Clin Invest,2019

4. New rising entities in cancer of unknown primary: Is there a real therapeutic benefit?

5. Narrative review on serous primary peritoneal carcinoma of unknown primary site: four questions to be answered

Cited by 18 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. An Overview of Immune Checkpoint Inhibitor Toxicities in Bladder Cancer;Toxicology Reports;2024-09

2. Advances in Cancer Research: Current and Future Diagnostic and Therapeutic Strategies;Biosensors;2024-02-16

3. Application of nitroxoline in urologic oncology – a review of evidence;Współczesna Onkologia;2024

4. Bibliometric analysis of research trends on the combination of immune checkpoint inhibitors and PARP inhibitors in solid tumors;Heliyon;2024-01

5. Immune checkpoint inhibitors in patients with cancers of unknown primary;European Journal of Cancer;2023-12

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号京ICP备18003416号-3